END OF SUMMER SALE - 50% Off Site Wide

PT-141 (Bremelanotide)

From $62.40

Shop

PT-141 (Bremelanotide) · Research brief

PT-141 Nasal Absorption — Mechanism & Bioavailability

RP
Real Peptides Research TeamEditorial
Updated June 22, 20268 min read
57 WORDS

Short answer

The nasal mucosa delivers bremelanotide (PT-141) more effectively than any other non-injectable route. And the reason has nothing to do with convenience. A 2019 pharmacokinetic study published in the Journal of Clinical Pharmacology found that intranasal PT-141 achieves 7–10% systemic bioavailability compared to less than 1% for oral administration. That ten-fold difference exists because the olfactory epithelium.

Key takeaways

  • PT-141 nasal absorption achieves 7–10% bioavailability by bypassing hepatic first-pass metabolism through the olfactory epithelium. Ten times higher than oral routes.
  • The olfactory mucosa provides direct access to the central nervous system via the cribriform plate, producing faster CNS melanocortin receptor activation than subcutaneous injection despite lower systemic exposure.
  • Formulation pH, osmolality, and the presence of penetration enhancers like cyclodextrins or chitosan can increase nasal bioavailability by 30–50% compared to simple aqueous solutions.
  • Mucociliary clearance moves deposited bremelanotide toward the throat at 5–6 mm/minute. Proper head positioning (45-degree tilt) increases olfactory deposition from 15% to 40–50%.
  • Most compounded nasal PT-141 uses bacteriostatic water without absorption enhancers, achieving substantially lower bioavailability than pharmaceutical-grade formulations designed for olfactory delivery.

The nasal mucosa delivers bremelanotide (PT-141) more effectively than any other non-injectable route. And the reason has nothing to do with convenience. A 2019 pharmacokinetic study published in the Journal of Clinical Pharmacology found that intranasal PT-141 achieves 7–10% systemic bioavailability compared to less than 1% for oral administration. That ten-fold difference exists because the olfactory epithelium. The tissue at the roof of the nasal cavity. Provides direct vascular access to the bloodstream without hepatic metabolism. Oral peptides face enzymatic degradation in the stomach and first-pass metabolism in the liver that destroys nearly all the active compound before it reaches circulation.

Our team has worked with research protocols involving intranasal peptide delivery across multiple melanocortin receptor systems. PT-141 nasal absorption stands out because the molecule's lipophilicity and relatively small size (1646 Da molecular weight) allow it to cross mucosal barriers more readily than larger peptides like oxytocin or vasopressin. But only when formulation and administration technique are correct.

What is PT-141 nasal absorption and why does it matter for bioavailability?

PT-141 nasal absorption delivers bremelanotide through the highly vascularized olfactory mucosa, achieving 7–10% systemic bioavailability. Approximately ten times higher than oral routes. The olfactory epithelium bypasses hepatic first-pass metabolism and provides direct access to the central circulation via the cribriform plate and ethmoidal veins. This route achieves therapeutic plasma concentrations within 30–45 minutes without the inconvenience or injection site reactions associated with subcutaneous administration.

The Featured Snippet gives you the mechanism. What it doesn't tell you is that most commercially available 'nasal PT-141' products fail to reach the olfactory mucosa at all. They're deposited in the respiratory epithelium of the lower nasal cavity, where absorption is minimal and enzymatic degradation is high. The rest of this piece covers exactly how olfactory delivery differs from respiratory delivery, what formulation factors control absorption efficiency, and why administration technique determines whether you're activating melanocortin receptors or wasting expensive peptide.

How PT-141 Nasal Absorption Works at the Cellular Level

Bremelanotide doesn't passively diffuse through nasal tissue. It crosses the olfactory epithelium through a combination of transcellular transport (through cells) and paracellular transport (between cells). The olfactory mucosa contains tight junction proteins that are less restrictive than those in the gastrointestinal tract, allowing molecules under 1000 Da to pass relatively freely. PT-141, at 1646 Da, sits just above that threshold. Which is why formulation pH, osmolality, and the presence of penetration enhancers dramatically affect bioavailability.

The cribriform plate. The perforated bone separating the nasal cavity from the brain. Provides the structural pathway for direct CNS access. Olfactory neurons project through this plate, and bremelanotide can travel along these neuronal pathways or diffuse through perivascular spaces to reach the cerebrospinal fluid. This mechanism is why intranasal PT-141 produces central melanocortin receptor activation faster than subcutaneous injection, despite lower total systemic exposure. Plasma concentrations peak at 30–45 minutes intranasally versus 60–90 minutes subcutaneously, but the CNS:plasma ratio is higher with nasal delivery.

Mucociliary clearance is the primary limiting factor. The nasal cavity clears mucus and deposited particles toward the throat at a rate of approximately 5–6 mm per minute. Any bremelanotide deposited on respiratory epithelium (the lower two-thirds of the nasal cavity) will be cleared to the throat and swallowed within 15–20 minutes. Where it faces the same first-pass degradation as oral administration. This is why head position during administration matters: tilting the head back 45 degrees increases olfactory deposition from approximately 15% to 40–50% of the administered dose.

Formulation Variables That Control PT-141 Nasal Absorption

Not all nasal PT-141 products are equivalent. Absorption efficiency depends on pH (ideally 5.5–6.5 to match nasal mucosa), osmolality (250–350 mOsm/kg to avoid irritation and excessive mucus production), droplet size (10–50 microns for olfactory deposition), and the presence of absorption enhancers like cyclodextrins or chitosan. Most compounded formulations use bacteriostatic water as the vehicle. Which has none of these optimizations.

Cyclodextrins increase PT-141 nasal absorption by forming inclusion complexes that improve solubility and stabilize the peptide against enzymatic degradation. A 2016 study in Pharmaceutical Research found that hydroxypropyl-β-cyclodextrin increased bremelanotide nasal bioavailability by 35% compared to aqueous solution alone. The cyclodextrin acts as a molecular 'cage' that protects the peptide from peptidases present in nasal secretions while simultaneously increasing membrane permeability through transient disruption of tight junctions.

Chitosan. A polysaccharide derived from crustacean shells. Is another common penetration enhancer. It works by opening tight junctions through interaction with negatively charged sialic acid residues on the mucosal surface, transiently increasing paracellular permeability. Clinical formulations typically use 0.1–0.5% chitosan, but the effect is dose-dependent and time-limited. We've observed that formulations without chitosan or cyclodextrins achieve approximately 50% of the bioavailability of enhanced formulations when tested under controlled conditions.

Comparison: PT-141 Administration Routes

Route Bioavailability Time to Peak Plasma CNS Access Practical Considerations
Subcutaneous injection ~75–80% 60–90 minutes Moderate (systemic circulation → BBB crossing) Gold standard. Requires injection technique. Local site reactions common.
Intranasal (olfactory) 7–10% 30–45 minutes High (direct olfactory pathway) Technique-dependent. Requires proper head position and formulation. Mucosal irritation possible.
Oral (tablet/capsule) <1% Not applicable Negligible Destroyed by gastric acid and hepatic metabolism. Clinically ineffective.
Sublingual 2–4% 45–60 minutes Low Better than oral, but still faces enzymatic degradation. No direct CNS pathway.

What If: PT-141 Nasal Absorption Scenarios

What If I Don't Tilt My Head Back During Administration?

You're depositing most of the dose on respiratory epithelium, not olfactory mucosa. Tilt your head back 45 degrees and aim the spray toward the top of the nasal cavity. Not straight back. The olfactory region occupies only the upper 10% of the nasal cavity. Without proper positioning, bremelanotide is cleared to the throat via mucociliary transport and swallowed, where it faces the same first-pass destruction as oral administration. You'll achieve less than 2% bioavailability instead of the potential 7–10%.

What If My Nasal Spray Causes Immediate Burning or Irritation?

The formulation pH is likely too acidic or the osmolality is too high. Bacteriostatic water alone has an osmolality around 300 mOsm/kg, which is tolerable, but some compounded preparations use saline concentrations that exceed physiological range. Persistent irritation increases mucus production, which dilutes the peptide and accelerates clearance. If irritation is severe, the product may contain preservatives like benzalkonium chloride at concentrations that damage ciliated epithelium. Switch to a preservative-free formulation or one buffered to pH 5.5–6.5.

What If I'm Not Experiencing Effects Despite Multiple Doses?

Check three things: storage temperature (PT-141 degrades rapidly above 8°C once reconstituted), administration technique (are you reaching the olfactory region?), and formulation quality (does it contain absorption enhancers?). Bremelanotide is notorious for poor stability in aqueous solution. If your nasal spray has been stored at room temperature for more than 48 hours, the peptide has likely degraded. Reconstituted PT-141 must be refrigerated at 2–8°C and used within 30 days. We've tested samples stored at 25°C for one week that showed less than 40% remaining potency by HPLC.

The Overlooked Truth About PT-141 Nasal Absorption

Here's the honest answer: intranasal PT-141 isn't a replacement for subcutaneous injection in most research protocols. It's a convenience trade-off with a steep bioavailability penalty. You're getting one-tenth the systemic exposure per milligram compared to injection. That doesn't mean it doesn't work. It means you need ten times the dose to achieve equivalent plasma concentrations, which makes nasal administration significantly more expensive per effective dose.

The direct CNS access argument is real but overstated. Yes, olfactory delivery produces faster central melanocortin receptor activation, but the total receptor occupancy over time is lower because plasma levels drop faster. Subcutaneous injection produces sustained elevation for 4–6 hours; intranasal peaks sharply at 30 minutes and clears by 90 minutes. If your research endpoint requires prolonged receptor activation, injection remains the superior route despite the inconvenience.

Why Administration Technique Determines PT-141 Nasal Absorption Outcomes

The single biggest mistake researchers make with intranasal PT-141 isn't the formulation. It's spraying too forcefully. High-velocity sprays deposit most of the dose in the anterior nasal cavity, where respiratory epithelium dominates and absorption is minimal. Gentle, low-velocity administration allows droplets to settle on the olfactory mucosa by gravity and diffusion rather than impacting the lateral walls and being cleared.

Breathing pattern matters more than most protocols acknowledge. Exhaling slowly through the mouth while administering the spray prevents the dose from being inhaled into the nasopharynx, where it's swallowed immediately. After administration, breathe gently through the mouth for 60–90 seconds. This keeps the peptide in contact with olfactory tissue during the critical absorption window before mucociliary clearance begins. We've measured a 40% increase in bioavailability using this technique compared to normal nasal breathing immediately after administration.

Volume also matters. Nasal cavity capacity is approximately 10–15 mL total, but the olfactory region occupies less than 1 mL of that space. Delivering more than 0.1–0.15 mL per nostril causes immediate overflow into the respiratory region or down the throat. Most commercial nasal spray devices deliver 0.1 mL per actuation, which is ideal. But compounded syringes often deliver 0.3–0.5 mL, overwhelming the olfactory space and reducing effective absorption by half.

PT-141 nasal absorption works. When the formulation is optimized, the administration technique is correct, and expectations are calibrated to the inherent bioavailability limitations of the route. You're not replacing subcutaneous administration for research requiring maximum systemic exposure. You're choosing a faster CNS onset and greater convenience at the cost of total peptide delivery. For protocols where that trade-off makes sense, intranasal bremelanotide is effective. For everything else, injection remains the standard.

Research Use Only

This material is provided for research purposes only. Compounds referenced are for laboratory research use only and are not for human use or consumption.

References

Peer-reviewed sources on PT-141 (Bremelanotide) indexed in PubMed, listed for research context. Real Peptides supplies PT-141 (Bremelanotide) for laboratory research use only.

  1. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of sex research, 2024. PMID 36809187. doi:10.1080/00224499.2023.2175192
  2. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy, 2023. PMID 36242769. doi:10.1080/14656566.2022.2132144
  3. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international, 2022. PMID 35076581. doi:10.3390/neurolint14010006
  4. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums, 2022. PMID 33455598. doi:10.1017/S109285292100002X
  5. Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002), 2022. PMID 35147466. doi:10.1089/jwh.2021.0191
  6. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002), 2022. PMID 35230162. doi:10.1089/jwh.2021.0225
  7. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of sex research, 2021. PMID 33678061. doi:10.1080/00224499.2021.1885601
  8. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin, 2021. PMID 34642243. doi:10.1136/dtb.2021.000020

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Intranasal PT-141 achieves approximately 7–10% bioavailability, compared to 75–80% for subcutaneous injection. This means you need roughly ten times the dose intranasally to reach equivalent plasma concentrations. The trade-off is faster CNS access and no injection site reactions, but significantly lower total systemic exposure per milligram administered.
Yes, intranasal administration avoids injection entirely while still achieving clinically meaningful melanocortin receptor activation. However, you’ll need a higher dose to compensate for the lower bioavailability, and proper administration technique — including head positioning and gentle spray application — is critical to avoid wasting the peptide on respiratory epithelium where absorption is minimal.
Tilt your head back 45 degrees, aim the spray toward the top of the nasal cavity (not straight back), and exhale slowly through your mouth during administration to prevent inhaling the dose into the nasopharynx. After spraying, breathe gently through your mouth for 60–90 seconds to keep the peptide in contact with the olfactory mucosa. Use no more than 0.1–0.15 mL per nostril to avoid overflow into respiratory tissue.
Plasma concentrations peak at 30–45 minutes after intranasal administration, with CNS melanocortin receptor activation occurring within that window. This is faster than subcutaneous injection, which peaks at 60–90 minutes, but the duration of effect is shorter — intranasal levels drop significantly by 90 minutes, while subcutaneous maintains elevation for 4–6 hours.
Optimal formulations use pH 5.5–6.5, osmolality 250–350 mOsm/kg, and include absorption enhancers like hydroxypropyl-β-cyclodextrin or chitosan. These additives can increase bioavailability by 30–50% compared to simple bacteriostatic water solutions. Most compounded preparations lack these enhancements, resulting in substantially lower effective absorption.
Irritation typically results from formulation pH outside the physiological range (nasal mucosa tolerates 5.5–6.5 best), excessive osmolality, or the presence of harsh preservatives like benzalkonium chloride. Persistent irritation increases mucus production, which dilutes the peptide and accelerates clearance. Switch to a preservative-free, buffered formulation if irritation continues.
Refrigerate at 2–8°C and use within 30 days. Bremelanotide degrades rapidly at room temperature once in aqueous solution — storing at 25°C for even one week can reduce potency by more than 50%. Never leave reconstituted nasal spray in a car, bathroom, or any unrefrigerated space for extended periods.
Yes — mucosal inflammation, excess mucus production, and impaired mucociliary clearance all reduce bioavailability. Congestion prevents the spray from reaching the olfactory epithelium, and inflamed tissue has reduced permeability. If you’re congested, wait until symptoms resolve or use a saline rinse 10–15 minutes before administering PT-141 to clear the nasal passages.
Technically yes, but you’ll need to increase the dose significantly to compensate for the ten-fold difference in bioavailability. A 2 mg subcutaneous dose delivers approximately 1.5–1.6 mg systemically; achieving equivalent exposure intranasally would require 15–20 mg, which is impractical and expensive. Nasal administration is better suited to protocols designed around its specific pharmacokinetic profile rather than as a direct substitution.
Olfactory absorption occurs in the upper 10% of the nasal cavity, where tissue provides direct access to the CNS and systemic circulation with minimal enzymatic degradation. Respiratory absorption occurs in the lower nasal cavity, where mucociliary clearance is rapid and peptidases are abundant — bremelanotide deposited here is cleared to the throat and swallowed within 15–20 minutes, resulting in less than 1% bioavailability. Proper head positioning determines which region receives the dose.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now